Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCEL
Previous Symbol
CUSIPN/A
Phone800-556-0311
Debt
Debt-to-Equity Ratio0.14
Current Ratio7.96
Quick Ratio7.71
Price-To-Earnings
Trailing P/E Ratio-33.84
Forward P/E Ratio-73.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$63.92 million
Price / Sales11.48
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book26.03
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-17,280,000.00
Net Margins-15.80%
Return on Equity-17.39%
Return on Assets-11.24%
Miscellaneous
Employees205
Outstanding Shares43,350,000
Market Cap$736.47 million
OptionableOptionable
Vericel (NASDAQ:VCEL) Frequently Asked Questions
What is Vericel's stock symbol?
Vericel trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) announced its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.09. The biotechnology company earned $22.50 million during the quarter, compared to analysts' expectations of $18.14 million. Vericel had a negative net margin of 15.80% and a negative return on equity of 17.39%. The company's revenue for the quarter was up 57.3% compared to the same quarter last year. View Vericel's Earnings History.
When is Vericel's next earnings date?
What guidance has Vericel issued on next quarter's earnings?
Vericel issued an update on its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $87-90 million, compared to the consensus revenue estimate of $81.57 million.
What price target have analysts set for VCEL?
5 equities research analysts have issued 12 month price objectives for Vericel's shares. Their predictions range from $14.00 to $20.00. On average, they anticipate Vericel's stock price to reach $16.75 in the next twelve months. This suggests that the stock has a possible downside of 0.1%. View Analyst Price Targets for Vericel.
What is the consensus analysts' recommendation for Vericel?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.
Has Vericel been receiving favorable news coverage?
Media coverage about VCEL stock has trended very positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vericel earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Spark Therapeutics (ONCE), Editas Medicine (EDIT), Autolus Therapeutics (AUTL) and Solid Biosciences (SLDB).
Who are Vericel's key executives?
Vericel's management team includes the folowing people:
- Mr. Dominick C. Colangelo, CEO, Pres & Director (Age 54)
- Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 55)
- Mr. Daniel R. Orlando, Chief Operating Officer (Age 53)
- Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
- Ms. Heidi Hassen, Sr. Director of HR
Who are Vericel's major shareholders?
Vericel's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.71%), Acadian Asset Management LLC (1.13%), Teachers Advisors LLC (1.03%), Castleark Management LLC (0.98%), Mutual of America Capital Management LLC (0.95%) and Panagora Asset Management Inc. (0.79%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.
Which major investors are selling Vericel stock?
VCEL stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Castleark Management LLC, Wells Fargo & Company MN, PNC Financial Services Group Inc., Redmile Group LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and BlueMountain Capital Management LLC. Company insiders that have sold Vericel company stock in the last year include Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Insider Buying and Selling for Vericel.
Which major investors are buying Vericel stock?
VCEL stock was bought by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, FMR LLC, Panagora Asset Management Inc., Point72 Asset Management L.P., BlackRock Inc., AQR Capital Management LLC, Allianz Asset Management GmbH and Cadence Capital Management LLC. View Insider Buying and Selling for Vericel.
How do I buy shares of Vericel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel's stock price today?
One share of VCEL stock can currently be purchased for approximately $16.76.
How big of a company is Vericel?
Vericel has a market capitalization of $736.47 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.
What is Vericel's official website?
How can I contact Vericel?
Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]
MarketBeat Community Rating for Vericel (NASDAQ VCEL)
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
